Latest Market Development News

Pengana Private Equity Trust reported a significant decline in half-year profit for the period ending 31 December 2025, yet increased its interim distribution to unitholders. The Trust’s net asset value per unit showed a modest rise despite challenging market conditions.

VEEM Ltd posted a significant half-year loss of $19.5 million, driven by a 30% revenue decline and a $24.8 million impairment on gyro product development. Despite setbacks, new product launches and US defence market progress offer a hopeful outlook.

WA Kaolin reported $2.7 million in sales for the December quarter, secured a $1.5 million working capital loan, and restructured $20.4 million of debt, while focusing on plant improvements and cost reductions to address negative margins.

PolyNovo Limited reported a robust 25.2% increase in half-year revenue to A$75 million, driven by strong U.S. sales and product growth, despite a near break-even net profit impacted by a manufacturing slowdown and a fire at its R&D lab.

Pepper Money Limited reported a record-breaking 2025 financial year, driven by strong growth in originations and assets under management, alongside enhanced ESG reporting and a significant acquisition proposal.

Acrow Limited reaffirms its first half FY26 revenue guidance with a 22% increase year-on-year, driven by robust demand in key Australian regions and strategic capital investments.

Deterra Royalties Limited has reported a record half-year net profit after tax of A$87.2 million, driven by strong revenue growth from its core Mining Area C royalty and successful divestment of non-core assets. The company also declared a higher fully franked interim dividend and advanced its Thacker Pass lithium project in Nevada.

Australian Vanadium Limited has responded to an ASX price query following a sharp rise in its share price and trading volume, denying any undisclosed information behind the market activity.

Tamawood Limited has reported a robust interim financial performance for the half year ended December 2025, showcasing significant growth in revenue, profit, and net tangible assets per share. The company’s reinstated dividend reinvestment plan and upcoming dividend review add to investor interest.

Impact Minerals has identified a promising standalone process to produce sulphate of potash and hydrochloric acid from lake clays in Western Australia, potentially reducing reliance on imports and addressing local industrial demand.

Vitrafy Life Sciences has delivered key milestones in the first half of FY26, including a strategic partnership with IMV Technologies and progress in clinical studies, while maintaining a strong cash position to support its U.S. expansion and product launches.

Cyclopharm has reported a record $32.3 million in operating revenue for FY2025, led by explosive growth in its U.S. Technegas market following FDA approval. The company reaffirms its ambitious target of 250–300 U.S. installations by mid-2026 amid strong clinical momentum.